X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2943) 2943
Publication (297) 297
Book Review (48) 48
Book Chapter (17) 17
Conference Proceeding (7) 7
Dissertation (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (2183) 2183
rituximab (1849) 1849
anti-cd20 monoclonal-antibody (1770) 1770
index medicus (1228) 1228
oncology (911) 911
antibodies, monoclonal - therapeutic use (870) 870
female (869) 869
antibodies, monoclonal, murine-derived (861) 861
male (832) 832
non-hodgkins-lymphoma (791) 791
hematology (758) 758
middle aged (715) 715
therapy (682) 682
adult (661) 661
aged (563) 563
treatment outcome (544) 544
chronic lymphocytic-leukemia (459) 459
antineoplastic agents - therapeutic use (452) 452
b-cell lymphoma (444) 444
animals (441) 441
immunology (421) 421
anti-cd20 (407) 407
follicular lymphoma (396) 396
anti-cd20 antibody (368) 368
antibodies, monoclonal - administration & dosage (339) 339
chemotherapy (331) 331
lymphoma (327) 327
immunotherapy (317) 317
antineoplastic combined chemotherapy protocols - therapeutic use (315) 315
cancer (308) 308
antigens, cd20 - immunology (304) 304
lymphomas (269) 269
care and treatment (263) 263
monoclonal antibodies (261) 261
transplantation (251) 251
b-lymphocytes - immunology (245) 245
mice (234) 234
antibodies, monoclonal - adverse effects (230) 230
low-grade (229) 229
cd20 (228) 228
radioimmunotherapy (225) 225
antibodies, monoclonal, murine-derived - therapeutic use (220) 220
efficacy (220) 220
pharmacology & pharmacy (220) 220
aged, 80 and over (211) 211
immunologic factors - therapeutic use (211) 211
antibodies, monoclonal - pharmacology (204) 204
in-vivo (202) 202
lymphoma, b-cell - drug therapy (202) 202
rheumatoid-arthritis (193) 193
phase-ii (191) 191
systemic-lupus-erythematosus (178) 178
phase-ii trial (177) 177
b-lymphocytes - drug effects (175) 175
lymphoma, non-hodgkin - drug therapy (175) 175
hemic and lymphatic diseases (173) 173
rheumatology (169) 169
trial (169) 169
drug therapy (168) 168
medicine & public health (161) 161
antineoplastic agents - administration & dosage (159) 159
disease-free survival (159) 159
adolescent (158) 158
clinical trials as topic (158) 158
health aspects (157) 157
medicine, research & experimental (151) 151
remission induction (151) 151
lymphoma, follicular - drug therapy (149) 149
b-cell depletion (148) 148
apoptosis (144) 144
prognosis (143) 143
research (143) 143
analysis (140) 140
antineoplastic agents - pharmacology (140) 140
chop chemotherapy (140) 140
recurrence (140) 140
immune system diseases (138) 138
b cells (137) 137
non-hodgkin's lymphoma (137) 137
antibodies, monoclonal - immunology (135) 135
leukemia, lymphocytic, chronic, b-cell - drug therapy (135) 135
combined modality therapy (134) 134
in-vitro (133) 133
safety (133) 133
antibodies (128) 128
monoclonal-antibody (128) 128
antineoplastic agents (126) 126
disease (124) 124
stem-cell transplantation (124) 124
abridged index medicus (123) 123
follow-up studies (123) 123
retrospective studies (123) 123
b-cells (122) 122
double-blind (122) 122
immunosuppressive agents - therapeutic use (122) 122
non-hodgkin's lymphomas (121) 121
monoclonal antibody (120) 120
dermatology (118) 118
medicine, general & internal (118) 118
time factors (118) 118
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2815) 2815
French (63) 63
German (33) 33
Spanish (20) 20
Korean (5) 5
Russian (5) 5
Japanese (4) 4
Chinese (3) 3
Turkish (3) 3
Czech (2) 2
Polish (2) 2
Portuguese (2) 2
Dutch (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of drugs in dermatology : JDD, ISSN 1545-9616, 12/2018, Volume 17, Issue 12, pp. 1338 - 1339
Rituximab is a chimeric anti-CD20 monoclonal antibody that is very effective in treating patients with pemphigus vulgaris. Though infrequent, the development... 
PATIENT | ANTI-CD20 ANTIBODY | RITUXIMAB | DERMATOLOGY
Journal Article
Blood, ISSN 0006-4971, 2009, Volume 113, Issue 16, pp. 3716 - 3725
Distinct genes encode 6 human receptors for IgG (hFc gamma Rs), 3 of which have 2 or 3 polymorphic variants. The specificity and affinity of individual hFc... 
DEPENDENT CELLULAR CYTOTOXICITY | WEGENERS-GRANULOMATOSIS | RHEUMATOID-ARTHRITIS | SYSTEMIC-LUPUS-ERYTHEMATOSUS | NATURAL-KILLER-CELLS | ANTI-CD20 MONOCLONAL-ANTIBODY | HUMAN-NEUTROPHILS | LIGAND-BINDING | ALLELIC POLYMORPHISM | THERAPEUTIC ACTIVITY | HEMATOLOGY
Journal Article
Scandinavian Journal of Gastroenterology, ISSN 0036-5521, 05/2017, Volume 52, Issue 5, pp. 606 - 608
Journal Article
Blood, ISSN 0006-4971, 2013, Volume 122, Issue 23, pp. 3723 - 3734
The management of chronic lymphocytic leukemia (CLL) is undergoing profound changes. Several new drugs have been approved for CLL treatment (fludarabine,... 
MAMMALIAN TARGET | ALEMTUZUMAB | PHASE-II TRIAL | FLUDARABINE PLUS CYCLOPHOSPHAMIDE | ANTI-CD20 ANTIBODY | RITUXIMAB | MONOCLONAL-ANTIBODY | 1ST-LINE THERAPY | COMBINATION | HEMATOLOGY | PREVIOUSLY UNTREATED PATIENTS
Journal Article
Pediatric Research, ISSN 0031-3998, 10/2018, Volume 84, Issue 4, pp. 520 - 526
BACKGROUND: Rituximab, a monoclonal antibody targeting B lymphocytes, effectively sustains remission in steroid-dependent nephrotic syndrome (SDNS). We studied... 
RESISTANT | MULTICENTER | ACTIVATION | EFFICACY | SAFETY | ANTI-CD20 ANTIBODY | PEDIATRICS | RECONSTITUTION | EXPRESSION | TH17 CELLS | CHILDREN | Lymphocytes
Journal Article
Autoimmunity Reviews, ISSN 1568-9972, 2013, Volume 12, Issue 11, pp. 1085 - 1090
Abstract The catastrophic variant of the antiphospholipid syndrome (APS) is characterized by thrombosis in multiple organs developing over a short period of... 
Allergy and Immunology | Refractory | Anti-CD20 | Rituximab | Catastrophic antiphospholipid syndrome | CELL DEPLETION THERAPY | SYSTEMIC LUPUS ERYTHAEMATOSUS | MANAGEMENT | INTERNATIONAL CONSENSUS STATEMENT | IMMUNOLOGY | CLASSIFICATION CRITERIA | Analysis | Antiphospholipid syndrome
Journal Article
Journal Article
Annales d'Endocrinologie, ISSN 0003-4266, 02/2017, Volume 78, Issue 1, pp. 20 - 26
Objectives Graves’ ophthalmopathy occurs in 50% of Graves’ disease cases. Treatment is based on smoking cessation, and control of the euthyroidism and ocular... 
Anti-CD20 | Optic neuropathy | Graves ophthalmopathy | Rituximab
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2005, Volume 23, Issue 3, pp. 474 - 481
Purpose Rituximab is an important therapeutic for Waldenstrom's macroglobulinemia (WM). Polymorphisms in FcgammaRIIIA (CD16) receptor expression modulate human... 
CELLS | ANTI-CD20 MONOCLONAL-ANTIBODY | ONCOLOGY | IGG | PHASE-II | FOLLICULAR LYMPHOMA | BINDING
Journal Article
Journal of Neurosurgery, ISSN 0022-3085, 06/2012, Volume 116, Issue 6, pp. 1318 - 1323
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 03/2014, Volume 370, Issue 12, pp. 1101 - 1110
Journal Article
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, ISSN 0732-183X, 02/2017, Volume 35, Issue 5, pp. 544 - 551
Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment,... 
THERAPY | RESPONSE CRITERIA | ONCOLOGY | CHOP | MONOCLONAL ANTI-CD20 ANTIBODY | RANDOMIZED CONTROLLED-TRIAL | COMBINATION | CHEMOTHERAPY PLUS RITUXIMAB | ELDERLY-PATIENTS | PROGNOSTIC VALUE | TRANSPLANTATION
Journal Article